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Radiation risk to dialysis patients
To the Editor: We read with interest the article of Kinsella
et al.,1 who report that diagnostic X-ray could cause as much
as a 7% increase of cancer-related mortality in long-term
dialysis patients. We have considered some of the same data,
and we reach a more benign conclusion.
We agree that occupational radiation exposure of 75mSv
might increase cancer-related mortality by 7%.2 But the subjects
of that report were only 31 years old at ﬁrst exposure, and all
were employed. The average age of subjects starting dialysis
in the United States and Europe is over 60 years,3 and they have
co-morbidities that will be lethal before they might die of
radiation injury. The latency of radiation-related solid cancers is
more than 10 years and the risk decreases with age at exposure.4
As Kinsella et al. point out in their Table 1, their dialysis patients
who received the higher radiation doses were on average 61 years
old, and had an yearly death rate of 26%. These patients will not
survive long enough to develop radiation-related cancers.
It is possible that in children on dialysis who undergo
excessive X-ray studies, one might see radiation-induced
leukemia, because that cancer has a shorter latency.5 But this
has not been reported.
The immediate beneﬁts of diagnostic X-ray far outweigh
the theoretical long-term risk claimed by Kinsella et al.
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Support for a protective effect of
bilirubin on diabetic nephropathy
in humans
To the Editor: We read with great interest the article by Fujii
et al.1 in which they found that bilirubin (BIL) may protect
against diabetic nephropathy (DN) in experimental animals,
which could pave the way for novel antioxidant therapies for
DN. Given these tantalizing results in animal models, it would
be of interest to see whether BIL also exerts protection against
DN in humans. To this end, we investigated the association
between BIL and DN in a case–control study. Cases of DN were
deﬁned as duration of type 2 diabetes 45 years, albuminuria
4300mg per day, and presence of diabetic retinopathy
(n¼ 32). Controls were type 2 diabetic patients without
nephropathy, matched for age, sex, and duration of diabetes
(n¼ 32). Age was 64±9 years, 54% were male, and median
(interquartile range, IQR) duration of diabetes was 15 (10–20)
years. Urinary albumin concentration was 752 (239–1074)mg/l
in cases versus 3 (3–6)mg/l in controls (Po0.001). Estimated
glomerular ﬁltration rate (GFR) was 65±23ml/min per
1.73m2 in cases versus 84±15ml/min per 1.73m2 in controls
(Po0.001). BIL was 5.5±2.3mmol/l in cases versus 7.3±
3.3mmol/l in controls (P¼ 0.02).
Our data extend the ﬁndings of Fujii et al. with support for
a protective effect of BIL on DN in humans. Further
intervention studies are needed to explore the possibility of
using BIL-based novel antioxidant therapies to halt the
progression of DN.
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The Authors Reply: We appreciate Zelle et al.,1 for their
interest in our article2 and for raising some insightful
comments in their letter entitled ‘Support for a protective
effect of bilirubin on diabetic nephropathy in humans’.
As for the relationship between serum bilirubin and diabetic
nephropathy, we ﬁrst showed the lower prevalence of
vascular complications, including nephropathy in diabetic
patients with Gilbert syndrome, a congenital hyperbilirubi-
nemia, as well as reduced markers of oxidative stress and
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